Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles

Cytokine

Volumn 61, Issue 2, 2013, Pages 345-348

  Shimizu, Masaki ^a   Nakagishi, Yasuo ^b   Yachie, Akihiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KOBE CHILDREN S HOSPITAL   (Japan)

Author keywords

Cytokine profiles; Interleukin 18; Interleukin 6; Systemic juvenile idiopathic arthritis

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; INTERLEUKIN 18; INTERLEUKIN 6; STEROID; STROMELYSIN;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEPATOSPLENOMEGALY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE COUNT; LYMPHADENOPATHY; MACROPHAGE ACTIVATION SYNDROME; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RASH; SCHOOL CHILD;

ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; HUMANS; INTERLEUKIN-18; INTERLEUKIN-6; MALE;

EID: 84873184774     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.11.025     Document Type: Article

References (15)

1. Frosch M., Roth J. New insights in systemic juvenile idiopathic arthritis-from pathophysiology to treatment. Rheumatology 2008, 47:121-125.
2. de Jager W., Hoppenreijs E.P., Wulffraat N.M., Wedderburn L.R., Kuis W., Prakken B.J. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007, 66:588-589.
3. Verbsky J.W., White A.J. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004, 31:2071-2075.
4. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
5. Gattorno M., Piccini A., Lasigliè D., Tassi S., Brisca G., Carta S., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008, 58:1505-1515.
6. Shimizu M., Nakagishi Y., Kasai K., Yamasaki Y., Miyoshi M., Takei S., et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012, 58:287-294.
7. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton. J Rheumatol 2001, 31(2004):390-392.
8. Ravelli A., Magni-Manzoni S., Pistorio A., Besana C., Foti T., Ruperto N., et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005, 146:598-604.
9. de Benedetti F., Massa M., Robbioni P., Ravelli A., Burgio G.R., Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34:1158-1163.
10. Pascual V., Allantaz F., Patel P., Palucka A.K., Chaussabel D., Banchereau J. How the study of children with rheumatic diseases identified interferon-α and interleukin-1 as novel therapeutic targets. Immunol Rev 2008, 223:39-59.
11. Shimizu M., Yokoyama T., Yamada K., Kaneda H., Wada H., Wada T., et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010, 49:1645-1653.
12. Mazodier K., Marin V., Novick D., Farnarier C., Robitail S., Schleinitz N., et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005, 106:3483-3489.
13. de Jager W., Vastert S.J., Beekman J.M., Wulffraat N.M., Kuis W., Coffer P.J., et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009, 60:2782-2793.
14. Miettunen P.M., Narendran A., Jayanthan A., Behrens E.M., Cron R.Q. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford) 2011, 50:417-419.
15. Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat Clin Pract Rheumatol 2006, 2:28-34.